AZ licenses Dizal’s lung cancer drug in $1.5bn deal
AstraZeneca has struck a $1.5bn agreement with Shanghai-based Dizal Pharmaceutical for global rights to sunvozertinib, an oral lung cancer therapy
AstraZeneca has struck a $1.5bn agreement with Shanghai-based Dizal Pharmaceutical for global rights to sunvozertinib, an oral lung cancer therapy
PATIENT priorities for treatment outcomes following brain–gut behavioural therapy (BGBT) differ from outcomes traditionally prioritised in clinical trials, such as anxiety and depression, according to a new US
A screen time app that lets friends cut their phone use together has won the £15,000 top prize in a
Your work spans clinical oncology, stem cell biology, public health leadership, and healthcare policy. How have those different domains influenced
Liver medicine is at a turning point. To deliver cutting-edge patient care and lead the field, healthcare professionals need a
DATA presented at AAIC 2026 showed that former elite soccer players had higher rates of depression and anxiety and lower
Roche subsidiary Genentech has signed a global drug discovery and licensing agreement with UK biotech Astex Pharmaceuticals worth up to
LEPROSY screening identified undiagnosed multibacillary disease and disability among incarcerated men in northeastern Brazil. Leprosy Screening Reveals Missed Cases Researchers
Breast cancer rates have risen rapidly among Asian American women over the past two decades, with some of the steepest
Elysium Health, the longevity science company, has published research in Frontiers in Aging suggesting a potential connection between NAD+ metabolism,